Life Sciences Venture Capital: Leading Venture Capitalists on how to Find, Manage, and Exit Successful Investments in Life Sciences Companies
Aspatore Books, 2005 - Business & Economics - 116 pages
Life Sciences Venture Capital is an authoritative, insider's perspective on the ins and outs of one of the most rapidly growing areas for venture capital investment today. Featuring managing directors and partners from some of the nation's leading VC firms, this book is a guide for investors and entrepreneurs alike on spotting the best investments in life sciences and seeing them through to a successful exit. The ten experts in this book walk readers through each phase of the investment selection process and reveal the indicators in technology, market, and management that make for a profitable venture. From overcoming the biggest risks in life sciences companies to the skills necessary for running a firm or investment team, this book is a useful tool for any VC hoping to capitalize on the next big thing in life sciences.About Inside the Minds: Inside the Minds provides readers with proven business intelligence from C-Level executives (Chairman, CEO, CFO, CMO, Partner) from the world's most respected companies nationwide, rather than third-party accounts from unknown authors and analysts. Each chapter is comparable to an essay/thought leadership piece and is a future-oriented look at where an industry, profession or topic is headed and the most important issues for the future. Through an exhaustive selection process, each author was hand-picked by the Inside the Minds editorial board to author a chapter for this book.This book is by: Gilbert H. Kliman, M.D, Managing Director, Life Sciences, InterWest Partners—“Tracking Down Large and Emerging Markets”; Howard D. Palefsky, General Partner, Montreux Equity Partners—“Investing in Capital-Efficient Life Science Companies for Superior Returns”; James P. Sherblom, Managing General Partner, Seaflower Ventures—“An Overview of Life Sciences Venture Capital”; Karen Boezi, Co-Founder & Managing Director, Thomas, McNerney & Partners—“Life Science: More Than Just a Financial Investment”; Robert (Robin) Bellas, General Partner, Morgenthaler Ventures—“Graceful Aging: The Next New Thing”; James M. Garvey, Managing General Partner, SV Life Sciences Advisers, Inc.—“Random Thoughts for a Not-So-Random Business”; James Glasheen, Ph.D., General Partner, Technology Partners—Making the Most of Investment Opportunities in Life Science”; Teri F. Willey & Thomas L. Churchwell, Managing Partners, ARCH Development Partners—“Finding Untapped Potential”; T. Forcht Dagi, MD, MPH,MBA, FACS, FCCM, Managing Partner, Cordova Ventures—“A Vision for Life Sciences Venture Capital: A Matter of Perspective.”
What people are saying - Write a review
We haven't found any reviews in the usual places.
acquired hy angel investors Aspatore beneﬁt biotechnology build business model capital efﬁciency capital-efﬁcient challenge chief executive ofﬁcer Churchwell clinical trials commercial company’s compounds Consenting Company Corporation deal device companies difﬁcult director disease diversiﬁcation early early-stage companies efﬁcacy emerging entrepreneurs evaluate exit value experience ﬁeld ﬁnancial ﬁnancing ﬁnd ﬁnding ﬁrst focus focused funds Glasheen hire important initial public offering innovation intellectual property invest in companies investment opportunities investor syndicate involved LASIK limited partners look management team medical device Medicare merger and acquisition milestones million partnership patent payors pharmaceutical Phase portfolio companies potential proﬁt public markets regulatory reimbursement returns round safety proﬁle sciences companies sciences industry sciences investing Sciences Venture Capital scientiﬁc sector signiﬁcant signiﬁcantly speciﬁc stage startups Successful Investments sustainable competitive advantage syndicate target therapeutic therapies valuation venture capital ﬁrm venture capital industry venture capitalists